Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
|Articles|July 1, 2006
Botulinum toxin A shows efficacy in treating BPH
Atlanta-Intraprostatic injection of botulinum toxin A (Botox) is a safe and effective treatment in patients with symptomatic BPH that results in improvements in symptoms and quality of life that may persist for up to 1 year, Chinese researchers reported at the AUA annual meeting here.
Advertisement
Advertisement
Related to this article
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Updated CAPItello-281 data showed a clinically meaningful benefit in OS when capivasertib was added to abiraterone and ADT in PTEN-deficient mHSPC.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
In TALAPRO-3, talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide (HR, 0.48; P < .0001) in HRR-mutated mAPMN/S prostate cancer.
Final phase 3 CA017-078 data show perioperative nivolumab plus GC did not significantly improve pCR (39.1% vs 29.6%) or EFS (HR, 0.94) vs GC alone in MIBC.
Daniel Heng, MD, discusses final LITESPARK-011 results, including sustained PFS benefit with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC.
In the randomized phase 2 PE-PE trial, median relapse-free survival was 25.4 months with pembrolizumab plus surgery or SABR vs 11.0 months with local therapy alone.
Advertisement
Advertisement
Trending on Urology Times
1
Updated CAPItello-281 data show numerical OS benefit with capivasertib in PTEN-deficient mHSPC
2
Adding darolutamide to ADT and radiation improves MFS in very high-risk localized prostate cancer
3
Durvalumab plus BCG improves DFS in papillary-only, BCG-naïve NMIBC
4
Alberto Briganti, MD, PhD, on the PROTEUS substudy in high-risk prostate cancer
5